NCT03286114 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03286114
Title	Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
Recruitment	Terminated
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	University of Michigan Cancer Center
Indications	myelodysplastic syndrome acute lymphoblastic leukemia acute myeloid leukemia
Therapies	Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA

Facility	Status	City	State	Zip	Country	Details
University of Michigan Cancer Center		Ann Arbor	Michigan	48109	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03286114Clinical Trial Detail